InVitae Corp (NASDAQ:NVTA) shares traded up 0% on Tuesday . The company traded as high as $9.25 and last traded at $9.15. 1,514,346 shares traded hands during trading, an increase of 406% from the average session volume of 299,341 shares. The stock had previously closed at $9.15.

A number of research analysts have recently weighed in on the company. Leerink Swann cut their price objective on InVitae Corp from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday. BidaskClub lowered InVitae Corp from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Zacks Investment Research lowered InVitae Corp from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $15.00 price objective (up previously from $14.00) on shares of InVitae Corp in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. InVitae Corp presently has an average rating of “Hold” and an average price target of $13.50.

InVitae Corp (NASDAQ:NVTA) last issued its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.02). The firm had revenue of $14.34 million for the quarter, compared to analysts’ expectations of $13.31 million. InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The company’s revenue for the quarter was up 157.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.77) EPS.

Several large investors have recently made changes to their positions in the stock. Verity Asset Management Inc. lifted its holdings in shares of InVitae Corp by 0.8% in the 2nd quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock valued at $101,000 after acquiring an additional 81 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in shares of InVitae Corp by 21.1% in the 1st quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock valued at $189,000 after acquiring an additional 2,987 shares during the last quarter. Donald L. Hagan LLC lifted its holdings in shares of InVitae Corp by 30.0% in the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 3,000 shares during the last quarter. American International Group Inc. lifted its holdings in shares of InVitae Corp by 31.3% in the 1st quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 4,090 shares during the last quarter. Finally, Credit Suisse AG lifted its holdings in shares of InVitae Corp by 22.9% in the 1st quarter. Credit Suisse AG now owns 25,178 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 4,694 shares during the last quarter.

WARNING: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/08/invitae-corp-nvta-trading-0-higher.html.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Stock Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related stocks with our FREE daily email newsletter.